IP Library Granted Patent US 9,884,830
Granted Patent B2
US 9,884,830 · App. 15/161,165 · Granted Feb 6, 2018

Synthesis of tetracyclines and analogues thereof

Inventors: Andrew G. Myers (Boston, MA); Mark G. Charest (Belle Mead, NJ); Christian D. Lerner (Binningen, CH); Jason D. Brubaker (Cheshire, CT); Dionicio R. Siegel (New York, NY)
Assignee: President and Fellows of Harvard College
C07D261/20C07C231/10C07C237/26C07D209/56C07D209/58C07D213/56C07D221/18C07D235/02C07D237/26C07D239/70C07D241/38C07D263/52C07D277/30C07D277/56C07D277/64C07D277/66C07D307/77
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,884,830
App. No.
15/161,165
Granted
Feb 6, 2018
Kind
B2
Abstract

The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The modular synthesis of tetracyclines and tetracycline analogs described provides an efficient and enantioselective route to a variety of tetracycline analogs and polycyclines previously inaccessible via earlier tetracycline syntheses and semi-synthetic methods. These analogs may be used as anti-microbial agents or anti-proliferative agents in the treatment of diseases of humans or other animals.

Claims (34)

1. A compound of Formula:

or a salt, isomer, or tautomer thereof;

wherein:

R 1 is hydrogen; halogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; acyl; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; —OR A ; —C(═O)R A ; —CO 2 R A ; —CN; —SCN; —SR A ; —SOR A ; —SO 2 R A ; —NO 2 ; —N(R A ) 2 ; —NHC(O)R A ; or —C(R A ) 3 ; wherein each occurrence of R A is independently hydrogen, a protecting group, aliphatic, heteroaliphatic, acyl, aryl, heteroaryl, alkoxy, aryloxy, alkylthio, arylthio, amino, alkylamino, dialkylamino, heteroaryloxy, or heteroarylthio;

R 2 is hydrogen; halogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; acyl; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; —OR B ; —C(═O)R B ; —CO 2 R B ; —CN; —SCN; —SR B ; —SOR B ; —SO 2 R B ; —NO 2 ; —N(R B ) 2 ; —NHC(O)R B ; or —C(R B ) 3 ; wherein each occurrence of R B is independently hydrogen, a protecting group, aliphatic, heteroaliphatic, acyl, aryl, heteroaryl, alkoxy, aryloxy, alkylthio, arylthio, amino, alkylamino, dialkylamino, heteroaryloxy, or heteroarylthio;

R 3 is hydrogen; halogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; acyl; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; —OR C ; —C(═O)R C ; —CO 2 R C ; —CN; —SCN; —SR C ; —SOR C ; —SO 2 R C ; —NO 2 ; —N(R C ) 2 ; —NHC(O)R C ; or —C(R C ) 3 ; wherein each occurrence of R C is independently hydrogen, a protecting group, aliphatic, heteroaliphatic, acyl, aryl, heteroaryl, alkoxy, aryloxy, alkylthio, arylthio, amino, alkylamino, dialkylamino, heteroaryloxy, or heteroarylthio;

R 4 is hydrogen; halogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; acyl; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; —OR D ; —C(═O)R D ; —CO 2 R D ; —CN; —SCN; —SR D ; —SOR D ; —SO 2 R D ; —NO 2 ; —N(R D ) 2 ; —NHC(O)R D ; or —C(R D ) 3 ; wherein each occurrence of R D is independently hydrogen, a protecting group, aliphatic, heteroaliphatic, acyl, aryl, heteroaryl, alkoxy, aryloxy, alkylthio, arylthio, amino, alkylamino, dialkylamino, heteroaryloxy, or heteroarylthio;

R 5 is hydrogen; halogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; acyl; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; —OR E ; —CN; —SCN; —SR E ; or —N(R E ) 2 ; wherein each occurrence of R E is independently hydrogen, a protecting group, aliphatic, heteroaliphatic, acyl, aryl, heteroaryl, alkoxy, aryloxy, alkylthio, arylthio, amino, alkylamino, dialkylamino, heteroaryloxy, or heteroarylthio;

each occurrence of R 7 is independently hydrogen; halogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; acyl; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; —OR G ; —C(═O)R G ; —CO 2 R G ; —CN; —SCN; —SR G ; —SOR G ; —SO 2 R G ; —NO 2 ; —N(R G ) 2 ; —NHC(O)R G ; or —C(R G ) 3 ; wherein each occurrence of R G is independently hydrogen, a protecting group, aliphatic, heteroaliphatic, acyl, aryl, heteroaryl, alkoxy, aryloxy, alkylthio, arylthio, amino, alkylamino, dialkylamino, heteroaryloxy, or heteroarylthio;

each occurrence of P′ is independently hydrogen or a protecting group; and

n is an integer in the range of 0 to 3, inclusive.

2. The compound of claim 1 , wherein each instance of R 1 , R 2 , R 3 , and R 4 is hydrogen.

3. The compound of claim 1 , wherein R 5 is —N(R E ) 2 , wherein each occurrence of R E is independently hydrogen, a protecting group, or lower (C 1 -C 6 ) alkyl.

4. The compound of claim 3 , wherein R 5 is —N(CH 3 ) 2 .

5. The compound of claim 1 , wherein each occurrence of R 7 is independently halogen; cyclic substituted or unsubstituted heteroaliphatic; substituted or unsubstituted heteroaryl; —OR G ; —CO 2 R G ; —CN; —SCN; —SR G ; —SOR G ; —SO 2 R G ; or —NHC(O)R G ; wherein each occurrence of R G is independently hydrogen, a protecting group, aliphatic, heteroaliphatic, acyl, aryl, heteroaryl, alkoxy, aryloxy, alkylthio, arylthio, amino, alkylamino, dialkylamino, heteroaryloxy, or heteroarylthio.

6. The compound of claim 5 , wherein at least one instance of R 7 is —NHC(O)R G .

7. The compound of claim 5 , wherein at least one instance of R 7 is halogen.

8. The compound of claim 7 , wherein halogen is —F.

9. The compound of claim 5 , wherein at least one instance of R 7 is —OR G .

10. The compound of claim 5 , wherein at least one instance of R 7 is cyclic substituted or unsubstituted heteroaliphatic.

11. The compound of claim 5 , wherein one instance of R 7 is —OR G and one instance of R 7 is cyclic substituted or unsubstituted heteroaliphatic.

12. The compound of claim 5 , wherein one instance of R 7 is halogen and one instance of R 7 is —NHC(O)R G .

13. The compound of claim 12 , wherein halogen is —F.

14. The compound of claim 5 , wherein one instance of R 7 is —OR G and one instance of R 7 is halogen.

15. The compound of claim 14 , wherein halogen is —F.

16. The compound of claim 1 , wherein n is 0.

17. The compound of claim 1 , wherein n is 1.

18. The compound of claim 1 , wherein n is 2.

19. The compound of claim 1 , wherein n is 3.

20. The compound of claim 1 , wherein the compound is:

or a salt, isomer, or tautomer thereof;

wherein:

n is 0, 1, or 2; and

P is hydrogen, lower alkyl group, acyl group, or a protecting group.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jan 13, 2021
From: HARVARD UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 054978/0459 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 19, 2016
From: MYERS, ANDREW G.; CHAREST, MARK G.; LERNER, CHRISTIAN D.; BRUBAKER, JASON D.; SIEGEL, DIONICIO R.
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 039481/0703 →
Continuity (6)
Continuation 14063868 · Oct 25, 2013
Continuation 12778797 · May 12, 2010
Division 11133789 · May 20, 2005
Provisional Application 60660947 · Mar 11, 2005
Provisional Application 60573623 · May 21, 2004
Related Publication 20160340325A1 · Nov 24, 2016